Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD)

Current Pharmaceutical Biotechnology

Volumn 13, Issue 2, 2012, Pages 278-291

  Kim, Moon Sun ^a   Kung, Sidney ^a   Grewal, Thomas ^a   Roufogalis, Basil D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Automated screening assays; Fibrates; Lipid droplet (LD) formation; Natural medicines; Nonalcoholic fatty liver disease (NAFLD); Thiazolidinediones (TZD)

Indexed keywords

ADENONSINE MONOPHOSPHATE DEPENDENT KINASE; ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; CYTOCHROME P450 4A; FAT DROPLET; FATTY ACID; FERRITIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; METFORMIN; MICRORNA; NATURAL PRODUCT; OMEGA N 3 FATTY ACID; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID; PIOGLITAZONE; RESISTIN; RETINOID X RECEPTOR; ROSIGLITAZONE; SILIBININ; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; BODY WEIGHT; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL (TOPIC); CONFOCAL MICROSCOPY; DISEASE MODEL; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG IDENTIFICATION; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY LIVER; FENUGREEK; GINSENG; GLYCOLYSIS; GYNOSTEMMA PENTAPHYLLUM; HIGH THROUGHPUT SCREENING; HUMAN; ILEX PARAGUARIENSIS; INSULIN SENSITIVITY; LIPOGENESIS; LIPOTOXICITY; LIVER GRAFT; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; POMEGRANATE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALACIA; SALACIA OBLONGA; SALACIA RETICULATE; SILYBUM MARIANUM; TEA; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; BIOLOGICAL AGENTS; FATTY LIVER; HUMANS; LIPID METABOLISM; MEDICINE, TRADITIONAL;

ANIMALIA;

EID: 84863079163     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799095310     Document Type: Review

References (181)

1. Xie, W.; Barwick, J.L.; Downes, M.; Blumberg, B.; Simon, C.M.; Nelson, M.C.; Neuschwander-Tetri, B.A.; Brunt, E.M.; Guzelian, P.S.; Evans, R.M. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature, 2000, 406(6794), 435-439.
2. Angulo, P. Nonalcoholic Fatty Liver Disease. N. Engl. J. Med., 2002, 346(16), 1221-1231.
3. Higuchi, H.; Gores, G.J. Mechanisms of liver injury: an overview. Curr. Mol. Med., 2003, 3(6), 483-490.
4. Bedogni, G.; Miglioli, L.; Masutti, F.; Tiribelli, C.; Marchesini, G.; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysus nutrition and liver study. Hepatology, 2005, 42(1), 44-52.
5. Amarapurkar, D.; Kamani, P.; Patel, N.; Gupte, P.; Kumar, P.; Agal, S.; Baijal, R.; Lala, S.; Chaudhary, D.; Deshpande, A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann. Hepatol., 2007, 6(3), 161-163.
6. Zhou, Y.; Zheng, S.; Lin, J.; Zhang, Q.J.; Chen, A. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPAR gamma in rat activated hepatic stellate cell in vitro. Lab. Invest., 2007, 87(5), 488-498.
7. Zhou, Y.J.; Li, Y.Y.; Nie, Y.Q.; Ma, J.X.; Lu, L.G.; Shi, S.L.; Chen, M.H.; Hu, P.J. Prevalence of fatty liver disease and its risk factors in the population of south china. World J. Gastroenterol., 2007, 13(47), 6419-6424.
8. Nagle, C.A.; Klett, E.L.; Coleman, R.A. Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res., 2009, 50(Suppl.), S74-S79.
9. Angulo, P.; Keach, J.C.; Batts, K.P.; Lindor, K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999, 30(6), 1356-1362.
10. Joy, D.; Thava, V.R.; Scott, B.B. Diagnosis of fatty liver disease: is biopsy necessary? Eur. J. Gastroenterol. Hepatol., 2003, 15(5), 539-543.
11. Saadeh, S.; Younossi, Z.M.; Remer, E.M.; Gramlich, T.; Ong, J.P.; Hurley, M.; Mullen, K.D.; Cooper, J.N.; Sheidan, M.J. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology, 2002, 123(3), 745-750.
12. Adams, L.A.; Sanderson, S.; Lindor, K.D.; Angulo, P. The histological course of non-alcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol., 2005, 42(1).
13. Adams, L.A.; Lindor, K.D.; Angulo, P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol., 2004, 99(7), 1316-1320.
14. Bradbury, M.W.; Burk P.D. Lipid metabolism in hepatic steatosis. Clin. Liver Dis., 2004, 8(3), 639-671.
15. Martin, S.; Parton, R.G. Lipid droplets: a unified view of a dynamic organelle. Nature Rev. Mol. Cell Biol., 2006, 7(5), 373-378.
16. Bostrom, P.; Andersson, L.; Rutberg, M.; Perman, J.; Lidberg, U.; Johansson, B.R.; Fernandez-Rodriguez, J.; Ericson, J.; Nilsson, T.; Boren, J.; Olofsson, S.O. SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat. Cell Biol., 2007, 9(11), 1286-1293.
17. Brasaemle, D.L. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J. Lipid Res., 2007, 48(12), 2547-2559.
18. Olofsson, S.O.; Boström, P.; Andersson, L.; Rutberg, M.; Perman, J.; Borén, J. Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim. Biophys. Acta, 2009, 1791(6), 448-458.
19. Kusminski, C.; Shetty, S.; Orci, L.; Unger, R.; Scherer, P. Diabetes and apoptosis: lipotoxicity. Apoptosis, 2009, 14(12), 1484-1495.
20. Murphy, S.; Martin, S.; Parton, R.G. Lipid droplets-organelle interactions; sharing the fats. Biochim. Biophys. Acta, 2009, 1791(6), 441-447.
21. Wan, H.C.; Melo, R.C.; Jin, Z.; Dvorak, A.M.; Weller, P.F. Roles and origins of leukocyte lipid bodies: proteomic and ultrastructural studies. FASEB J., 2007, 21(1), 167-178.
22. DiAugustine, R.P.; Schaefer, J.M.; Fouts, J.R. Hepatic lipid droplets. Isolation, morphology, and composition. Biochem. J., 1973, 132(2), 323-327.
23. Pilch, P.F.; Souto, R.P.; Liu, L.; Jedrychowski, M.P.; Berg, E.A.; Costello, C.E.; Gygi, S.P. Cellular spelunking: exploring adipocyte caveolae. J. Lipid Res., 2007, 48(10), 2103-2111.
24. Guo, Y.; Walther, T.C.; Rao, M.; Stuurman, N.; Goshima, G.; Terayama, K.; Wong, J.S.; Vale, R.D.; Walter, P.; Farese, R.V. Functional genomic screen reveals genes involved in lipid-droplet formation and utilization. Nature, 2008, 453(1795), 657-661.
25. Martin, S.; Parton, R.G. Caveolin, cholesterol, and lipid bodies. Semin. Cell. Dev. Biol., 2005, 16(2), 163-174.
26. Brasaemle, D.L.; Dolios, G.; Shapiro, L.; Wang, R. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J. Biol. Chem., 2004, 279(45), 46835-46842.
27. Martin, S.; Driessen, K.; Nixon, S.J.; Zerial, M.; Parton, R.G. Regulated localization of Rab18 to lipid droplets: Effects of lipolytic stimulation and inhibition of lipid droplet catabolism. J. Biol. Chem., 2005, 280(51), 42325-42335.
28. Pol, A.; Martin, S.; Fernandez, M.A.; Ferguson, C.; Carozzi, A.; Luetterforst, R.; Enrich, C.; Parton, R.G. Dynamic and regulated association of caveolin with lipid bodies: Modulation of lipid body motility and function by a dominant negative mutant. Mol. Biol. Cell., 2004, 15(1), 99-110.
29. Strey, C.W.; Winters, M.S.; Markiewski, M.M.; Lambris, J.D. Partial hepatectomy induced liver proteome changes in mice. Proteomics, 2005, 5(1), 318-325.
30. Bartz, R.; Li, W.H.; Venables, B.; Zehmer, J.K.; Roth, M.R.; Welti, R.; Anderson, R.G.; Liu, P.; Chapman, K.D. Lipidomics reveals that adiposomes store ether lipids and mediate phospholipid traffic. J. Lipid Res., 2007, 48(4), 837-847.
31. Beller, M.; Riedel, D.; Jänsch, L.; Dieterich, G.; Wehland, J.; Jäckle, H.; Kühnlein, R.P. Characterization of the Drosophila lipid droplet subproteome. Mol. Cell. Proteomics, 2006, 5(6), 1082-1094.
32. Cermelli, S.; Guo, Y.; Gross, S.P.; Welte, M.A. The lipid-droplet proteome reveals that droplets are a protein-storage depot. Curr. Biol., 2006, 16(18), 1783-1795.
33. Fujimoto, Y.; Itabe, H.; Sakai, J.; Makita, M.; Noda, J.; Mori, M.; Higashi, Y.; Kojima, S.; Takano, T. Identification of major proteins in the lipid droplet-enriched fraction isolated from the human hepatocyte cell line HuH7. Biochim. Biophys. Acta, 2004, 1644(1), 47-59.
34. Liu, P.; Ying, Y.; Zhao, Y.; Mundy, D.I.; Zhu, M.; Anderson, R.G. Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic. J. Biol. Chem., 2004, 279(5), 3787-3792.
35. Sato, S.; Fukasawa, M.; Yamakawa, Y.; Natsume, T.; Suzuki, T.; Shoji, I.; Aizaki, H.; Miyamura, T.; Nishijima, M. Proteomic profiling of LD proteins in hepatoma cell lines expressing hepatitis C virus core protein. J. Biochem., 2006, 139(5), 921-930.
36. Turro, S.; Ingelmo-Torres, M.; Estanyol, J.M.; Tebar, F.; Fernández, M.A.; Albor, C.V.; Gaus, K.; Grewal, T.; Enrich, C.; Pol, A. Identification and characterization of associated with lipid droplet protein 1: A novel membrane-associated protein that resides on hepatic lipid droplets. Traffic, 2006, 7(9), 1254-1269.
37. Umlauf, E.; Csaszar, E.; Moertelmaier, M.; Schuetz, G.J.; Parton, R.G.; Prohaska, R. Association of stomatin with lipid bodies. J. Biol. Chem., 2004, 279(22), 23699-23709.
38. Wu, C.C.; Howell, K.E.; Neville, M.C.; Yates, J.R.; McManaman, J.L. Proteomics reveal a link between the endoplasmic reticulum and lipid secretory mechanisms in mammary epithelial cells. Electrophoresis, 2000, 21(16), 3470-3482.
39. Listenberger, L.L.; Ostermeyer-Fay, A.G.; Goldberg, E.B.; Brown, W.J.; Brown, D.A. Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover. J. Lipid Res., 2007, 48(12), 2751-2761.
40. Motomura, W.; Inoue, M.; Ohtake, T.; Takahashi, N.; Nagamine, M.; Tanno, S.; Kohgo, Y.; Okumura, T. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem. Biophys. Res. Commun., 2006, 340(4), 1111-1118.
41. Imai, Y.; Varela, G.M.; Jackson, M.B.; Graham, M.J.; Crooke, R.M.; Ahima, R.S. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology, 2007, 132(5), 1947-1954.
42. Kallwitz, E.R.; McLachlan, A.; Cotler, S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol., 2008, 14(1), 22-28.
43. Tanaka, T.; Yamamoto, J.; Iwasaki, S.; Asaba, H.; Hamura, H.; Ikeda, Y.; Watanabe, M.; Magoori, K.; Ioka, R.X.; Tachibana, K.; Watanabe, Y.; Uchiyama, Y.; Sumi, K.; Iguchi, H.; Ito, S.; Doi, T.; Hamakubo, T.; Naito, M.; Auwerx, J.; Yanagisawa, M.; Kodama, T.; Sakai, J. Activation of peroxisome proliferator-activated receptor d induces fatty acid b-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA, 2003, 100(26), 15924-15929.
44. Seo, Y.S.; Kim, J.H.; Jo, N.Y.; Choi, K.M.; Baik, S.H.; Park, J.J.; Kim, J.S.; Byun, K.S.; Bak, Y.T.; Lee, C.H.; Kim, A.; Yeon, J.E. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J. Gastroentrol. Hepatol., 2008, 23(1), 102-109.
45. Torra, I.P.; Chinetti, G.; Duval, C.; Fruchart, J.C.; Staels, B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr. Opin. Lipidol., 2001, 12(3), 245-254.
46. Kota, B.P.; Huang, T.H.W.; Roufogalis, B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res., 2005, 51(2), 85-94.
47. Gervois, P.; Fruchart, J.C.; Staels, B. Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPAR alpha and PPAR gamma agonists. Int. J. Clin. Pract. Suppl., 2004, 58(143), 22-29.
48. Attie, A.D.; Krauss, R.M.; Gray-Keller, M.P.; Brownlie, A.; Miyazaki, M.; Kastelein, J.J.; Lusis, A.J.; Stalenhoef, A.F.; Stoehr, J.P.; Hayden, M.R.; Ntambi, J.M. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res., 2002, 43(11), 1899-1907.
49. Ip, E.; Farrell, G.C.; Robertson, G.; Hall, P.; Kirsch, R.; Leclercq, I. Central role of PPAR alpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology, 2003, 38(1), 123-132.
50. Pachikian, B.D.; Neyrinck, A.M.; Cani, P.D.; Portois, L.; Deldicque, L.; De Backer, F.C.; Bindels, L.B.; Sohet, F.M.; Malaisse, W.J.; Francaux, M.; Carpentier, Y.A.; Delzenne, N.M. Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol., 2008, 8, 21.
51. Reddy, J.K.; Hashimoto, T. Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: An adaptive metabolic system. Annu. Rev. Nutr., 2001, 21(1), 193-230.
52. Akbiyik, F.; Cinar, K.; Demirpence, E.; Ozsullu, T.; Tunca, R.; Haziroglu, R.; Yurdaydin, C.; Uzunalimoglu, O.; Bozkaya, H. Ligand-induced expression of peroxisome proliferator-activated receptor α and activation of fatty acid oxidation enzymes in fatty liver. Eur. J. Clin. Invest., 2004, 34(6), 429-435.
53. Harano, Y.; Yasui, K.; Toyama, T.; Nakajima, T.; Mitsuyoshi, H.; Mimani, M.; Hirasawa, T.; Itoh, Y.; Okanoue, T. Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int., 2006, 26(5), 613-620.
54. Svegliati-Baroni, G.; Candelaresi, C.; Saccomanno, S.; Ferretti, G.; Bachetti, T.; Marzioni, M.; De Minicis, S.; Nobili, L.; Salzano, R.; Omenetti, A.; Pacetti, D.; Sigmund, S.; Benedetti, A.; Casini, A. A model of insulin resistance and nonalcoholic steatohepatitis in rats: Role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol., 2006, 169(3), 846-860.
55. Cook, W.S.; Yeldandi, A.V.; Rao, M.S.; Hashimoto, T.; Reddy, J.K. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPARalpha. Biochem. Biophys. Res. Commun., 2000, 278(1), 250-257.
56. Neve, B.P.; Fruchart, J.-C.; Staels, B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol., 2000, 60(8), 1245-1250.
57. Chou, C.J.; Haluzik, M.; Gregory, C.; Dietz, K.R.; Vinson, C.; Gavrilova, O.; Reitman, K.L. WY14,643, a peroxisome proliferator-activated receptor a (PPARa) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem., 2002, 277(27), 24484-24489.
58. van Raalte, D.H.; Li, M.; Pritchard, P.H.; Wasan, K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res., 2004, 21(9), 1531-1538.
59. Haluzik, M.M.; Lacinova, Z.; Dolinkova, M.; Haluzikova, D.; Housa, D.; Horinek, A.; Vernerova, Z.; Kumstyrova, T.; Haluzik, M. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology, 2006, 147(9), 4517-4524.
60. Nagasawa, T.; Inada, Y.; Nakano, S.; Tamura, T.; Takahashi, T.; Maruyama, K.; Yamazaki, Y.; Kuroda, J.; Shibata, N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine-and choline-deficient diet. Eur. J. Pharmacol., 2006, 536(1-2), 182-191.
61. Nakamuta, M.; Morizono, S.; Soejima, Y.; Yoshizumi, T.; Aishima, S.; Takasugi, S.; Yoshimitsu, K.; Enjoji, M.; Kotoh, K.; Taketomi, A.; Uchiyama, H.; Shimada, M.; Nawata, H.; Maehara, Y. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation, 2005, 80(5), 608-612.
62. Perkins, J.D. Saying "yes" to obese living liver donors: Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Liver Transpl., 2006, 12(6), 1012-1016.
63. Keller, H.; Dreyer, C.; Medin, J.; Mahfoudi, A.; Ozato, K.; Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA, 1993, 90(6), 2160-2164.
64. Sekiya, M.; Yahagi, N.; Matsuzaka, T.; Najima, Y.; Nakakuki, M.; Nagai, R.; Ishibashi, S.; Osuga, J.; Yamada, N.; Shimano, H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology, 2003, 38(5), 529-1539.
65. Le Foll, C.; Corporeau, C.; Le Guen, V.; Gouygou, J.-P.; Berge, J.-P.; Delarue, J. Long-chain n-3 polyunsaturated fatty acids dissociate phosphorylation of Akt from phosphatidylinositol 3'-kinase activity in rats. Am. J. Physiol. Endocrinol. Metab., 2007, 292(4), E1223-1230.
66. Gutiérrez, A.M.; Reboredo, G.R.; Mosca, S.M.; Catalá, A. Nonenzymatic lipid peroxidation of microsomes and mitochondria from liver, heart and brain of the bird Lonchura striata: Relationship with fatty acid composition. Comp. Biochem. Physiol. A Mol. Integr. Physiol., 2007, 146(3), 415-421.
67. Bajaj, M.; Suraamornkul, S.; Hardies, L.J.; Pratipanawatr, T.; DeFrpmzp, R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int. J. Obes. Relat. Metab. Disord., 2004, 28(6), 783-789.
68. Jung, H.S.; Youn, B.-S.; Cho, Y.M.; Yu, K.-Y.; Park, H.J.; Shin, C.S.; Kim, S.Y.; Lee, H.K.; Park, K.S. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism, 2005, 54(3), 314-320.
69. Neuschwander-Tetri, B.A.; Brunt, E.M.; Wehmeier, K.R.; Oliver, D.; Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPARGamma Ligand Rosiglitazone. Hepatology, 2003, 38(4), 1008-1017.
70. Lutchman, G.; Modi, A.; Kleiner, D.E.; Promrat, K.; Heller, T.; Ghany, M.; Borg, B.; Loomba, R.; Liang, T.J.; Premkumar, A.; Hoofnagle, J.H. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology, 2007, 46(2), 424-429.
71. Ratziu, V.; Giral, P.; Jacqueminet, S.; Charlotte, F.; Hartemann-Heurtier, A.; Serfaty, L.; Podevin, P.; Lacorte, J.-M.; Bernhardt, C.; Bruckert, E.; Grimaldi, A.; Poynard, T. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology, 2008, 135(1), 100-110.
72. Solomon, S.S.; Mishra, S.K.; Cwik, C.; Rajanna, B.; Postlethwaite, A.E. Pioglita-zone and metformin reverse insulin resistance induced by tumor necrosis factor alpha in liver cells. Horm. Metab. Res., 1997, 29(8), 379-382.
73. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Zoli, M.; Melchionda, N. Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358(9285), 893-894.
74. Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Thumburu, K.T.; Bhadada, S.; Bhansali, A. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann. Hepatol., 2007, 6(4), 222-226.
75. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.V., J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108(8), 1167-1174.
76. Song, Z.; Deaciuc, I.; Zhou, Z.; Song, M.; Chen, T.; Hill, D.; McClain, C.J. Involvement of AMP-activated protein kinase in beneficial effects of betaine in high-sucrose diet-induced hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293(4), G894-G902.
77. Listenberger, L.L.; Han, X.; Lewis, S.E.; Cases, S.; Farese, R.V.; Ory, D.S.; Schaffer, J.E. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. USA, 2003, 100(6), 3077-3082.
78. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology, 2007, 45(6), 1366-1374.
79. Li, Z.Z.; Berk, M.; McIntyre, T.M.; Feldstein, A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: Role of stearoyl-CoA desaturase. J. Biol. Chem., 2009, 284(9), 5637-5644.
80. Bonow, R.O.; Eckel, R.H. Diet, obesity, and cardiovascular risk. N. Engl. J. Med., 2003, 348(21), 2057-2058.
81. Samuel, V.T.; Liu, Z.X.; Qu, X.; Elder, B.D.; Bilz, S.; Befroy, D.; Romanelli, A.J.; Shulman, G.I. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem., 2004, 279(31), 32345-32353.
82. World Health Organisation. Traditional medicine. Fact sheets, 2008, No 134, http://www.who.int/mediacentre/factsheets/fs134/en/.
83. Shih, C.C.; Lin, C.H.; Lin, W.L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res. Clin. Pract., 2008, 81(2), 134-143.
84. Chan, L.L.; Chen, Q.; Go, A.G.; Lam, E.K.; Li, E.T. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J. Nutr, 2005, 135(11), 2517-2523.
85. Nerurkar, P.V.; Pearson, L.; Efird, J.T.; Adeli, K.; Theriault, A.G.; Nerurkar, V.R. Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J. Nutr., 2005, 135(4), 702-706.
86. Basch, E.; Ulbrich, T.C.; Kuo, G.; Szapary, P.; Smith, M. Therapeutic applications of Fenugreek. Altern. Med. Rev., 2003, 8(1), 20-27.
87. Sharma, R.D.; Sarkar, A.; Hazre, D.K.; Misra, B.; Singh, J.B.; Mahesheari, B.B.; Sharma, S.K. Hypolipidaemic effect of fenugreek seeds: a chronic study in non-insulin dependent diabetic patients. Phytother. Res., 1996, 10(4), 332-334.
88. Raju, J.; Bird, R.P. Alleviation of hepatic steatosis accompanied by modulation of plasma and liver TNF-alpha levels by Trigonella foenum graecum (fenugreek) seeds in Zucker obese (fa/fa) rats. Int. J. Obes. (Lond), 2006, 30(8), 1298-1307.
89. Yadav, U.C.; Moorthy, K.; Baquer, N.Z. Effects of sodiumorthovanadate and Trigonella foenum-graecum seeds on hepatic and renal lipogenic enzymes and lipid profile during alloxan diabetes. J. Biosci., 2004, 29(1), 81-91.
90. Jin, X.; Zheng, R.h.; Li, Y.m. Green tea consumption and liver disease: a systematic review. Liver Int., 2008, 28(7), 990-996.
91. Imai, K.; Nakachi, K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ, 1995, 310(6981), 693-696.
92. Shrestha, S.; Ehlers, S.J.; Lee, J.Y.; Fernandez, M.L.; Koo, S.I. Dietary green tea extract lowers plasma and hepatic triglycerides and decreases the expression of sterol regulatory element-binding protein-1c mRNA and its responsive genes in fructose-fed, ovariectomized rats. J. Nutr., 2009, 139(4), 640-645.
93. Vuksan, V.; Stavro, M.P.; Sievenpiper, J.L.; Beljan-Zdravkovic, U.; Leiter, L.A.; Josse, R.G.; Xu, Z. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care, 2000, 23(9), 1221-1226.
94. Soonthornpun, S.; Rattarasarn, C.; Leelawattana, R.; Setasuban, W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res. Clin. Pract., 1999, 46(1), 23-27.
95. Turner, R.C. The U.K. Prospective Diabetes Study. A review. Diabetes Care, 1998, 21(3), C35-C38.
96. Muwalla, M.M.; Abuirmmeileh, N.M. Suppression of avian hepatic cholesterogenesis by dietary ginseng. J. Nutr. Biochem., 1990, 1(10), 518-521.
97. Zheng, X.; Yan, Y. The effect of ginsenosides of ginseng stem and leaf (GSL) on the lipid regulation and lipid peroxidation in chronic hyperlipidemic rabbits. Zhongguo Yaolixue Tonbao, 1991, 7, 110-116.
98. Yoon, M.; Lee, H.; Jeong, S.; Kim, J.J.; Nicol, C.J.; Kim, M.; Cho, B.G.; Oh, G.T. Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng. Br. J. Pharmacol., 2003, 138(7), 1295-1302.
99. Liu, C.X.; Xiao, P.G. Recent advances on ginseng research in China. J. Ethnopharmacol., 1992, 36(1), 27-38.
100. Kim, Y.S.; Kim, D.S.; Kim, S.I. Ginsenoside Rh2 and Rh3 induce differentiation of HL-60 cells into granulocytes: modulation of protein kinase C isoforms during differentiation by ginsenoside Rh2. Int. J. Biochem. Cell. Biol., 1998, 30(3), 327-338.
101. Cho, W.C.; Chung, W.S.; Lee, S.K.; Leung, A.W.; Cheng, C.H.; Yue, K.K. Ginsenoside Re of Panax ginseng possesses significant antioxidant and anti-hyperlipidemic efficacies in streptozotocininduced diabetic rats. Euro. J. Pharmacol., 2006, 550(1-3), 173-179.
102. Trinh, H.T.; Han, S.J.; Kim, S.W.; Lee, Y.C.; Kim, D.H. Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J. Microbiol. Biotechnol., 2007, 17(7), 1127-1133.
103. Yokozawa, T.; Kobayashi, T.; Kawao, A.; Oura, H.; Kawashima, Y. Hyperlipidemia-improving effects of ginsenoside-Rb2 in cholesterol-fed rat. Chem. Pharm. Bull. (Tokyo), 1985, 33(2), 722-729.
104. Zhang, X.M.; Qu, S.C.; Sui, D.Y.; Yu, X.F.; Lv, Z.Z. Effects of ginsenoside-Rb on blood lipid metabolism and anti-oxidation in hyperlipidemia rats. Zhongguo Zhong Yao Za Zhi, 2004, 29(11), 1085-1088.
105. Matsuda, D.; Ohshiro, T.; Ohba, M.; Jiang, W.; Hong, B.; Si, S.; Tomoda, H. The molecular target of rubimaillin in the inhibition of lipid droplet accumulation in macrophages. Biol. Pharm. Bull., 2009, 32(8), 1317-1320.
106. Chou, S.C.; Chen, K.W.; Hwang, J.S.; Lu, W.T.; Chu, Y.Y.; Lin, J.D.; Chang, H.J.; See, L.C. The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease. Altern. Ther. Health Med., 2006, 12(3), 34-39.
107. Norberg, A.; Hoa, N.K.; Liepinsh, E.; Van Phan, D.; Thuan, N.D.; Jörnvall, H.; Sillard, R.; Ostenson, C.G. A novel insulin-releasing substance, phanoside, from the plant Gynostemma pentaphyllum. J. Biol. Chem., 2004, 279(40), 41361-41367.
108. Xu, K.Z.; Zhu, C.; Kim, M.S.; Yamahara, J.; Li, Y. Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity. J Ethnopharmacol., 2009, 123(2), 280-287.
109. Pradhan, S.C.; Girish, C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res., 2006, 124(5), 491-504.
110. Loguercio, C.; Federico, A.; Trappoliere, M.; Tuccillo, C.; de Sio, I.; Di Leva, A.; Niosi, M.; D'Auria, M.V.; Capasso, R.; Del Vecchio Blanco, C.; Group., R.S. The effect of a silybim-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: A pilot study. Dig. Dis. Sci., 2007, 52(9), 2387-2395.
111. Fuchs, E.C.; Weyhenmeyer, R.; Weiner, O.H. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung, 1997, 47(12), 1883-1887.
112. Yoo, H.G.; Jung, S.N.; Hwang, Y.S.; Park, J.S.; Kim, M.H.; Jeong, M.; Ahn, S.J.; Ahn, B.W.; Shin, B.A.; Park, R.K.; Jung, Y.D. Involvement of NF-kB and caspases in silibinin-induced apoptosis of endothelial cells. Int. J. Mol. Med., 2004, 13(1), 81-86.
113. Kaur, P.; Kaur, S.; Kumar, S.; Singh, P. Rubia cordifolia L. and Glycyrrhiza glabra L. medicinal plants as potential source of COX-2 inhibitors. Am. J. Biomed. Sci., 2010, 2(2), 108-120.
114. Andersen, T.; Fogh, J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J. Hum. Nutr. Diet., 2001, 14(3), 243-250.
115. Kraemer, K.H.; Taketa, A.T.C.; Schenkel, E.P.; Gosmann, G.; Guillaume, D. Matesaponin 5, a highly polar saponin from Ilex paraguariensis. Phytochemistry, 1996, 42(4), 1119-1122.
116. Pomilio, A.B.; Trajtemberg, S.; Vitale, A.A. High-performance capillary electrophoresis analysis of mate infusions prepared from stems and leaves of Ilex paraguariensis using automated micellar electrokinetic capillary chromatography. Phytochem. Anal., 2002, 13(4), 235-241.
117. Pang, J.; Choi, Y.; Park, T. Ilex paraguariensis extract ameliorates obesity induced by high-fat diet, potential role of AMPK in the visceral adipose tissue. Arch. Biochem. Biophys., 2008, 476(2), 178-185.
118. Rodriguez de Sotillo, D.V.; Hadley, M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J. Nut. Biochem., 2002, 13(12), 717-726.
119. Jayaweera, D.M.A. Medicinal plants (Indigenous and Exotic) used in Ceylon, Part I. Colombo, National Science Council of Sri Lanka, 1981.
120. Ganapathy, P.M. Indian Medicinal Plants. Orient Longman, 1993, Vol. 5. 47-48.
121. 4- induced liver injury in mice. Biol. Pharm. Bull., 2002, 25(1), 72-76.
122. Huang, T.H.; Peng, G.; Li, G.Q.; Yamahara, J.; Roufogalis, B.D.; Li, Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-a. Toxicol. Appl. Pharmacol., 2005, 210(3), 225-235.
123. Fujimoto, M.; Tsuneyama, K.; Kinoshita, H.; Goto, H.; Takano, Y.; Selmi, C.; Keen, C.L.; Gershwin, M.E.; Shimada, Y. The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. Ann. N. Y. Acad. Sci., 2010, 1190(1), 151-158.
124. Shimizu, I.; Ma, Y.R.; Mizobuchi, Y.; Liu, F.; Miura, T.; Nakai, Y.; Yasuda, M.; Shiba, M.; Horie, T.; Amagaya, S.; Kawada, N.; Hori, H.; Ito, S. Effects of sho-saiko-to, a japanese herbal medicine, on hepatic fibrosis in rats. Hepatology, 1999, 29(1), 149-160.
125. Hong, X.Z.; Li, L.D.; Wu, L.M. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin. Exp. Pharmacol. Physiol., 2007, 34(1-2), 27-35.
126. Kashireddy, P.; Rao, M.S. Lack of peroxisome proliferatoractivated receptor alpha enhances methionine and choline deficient diet-induced steatohepatitis. Hep. Res., 2004, 30(2), 104-110.
127. Sharma, A.M.; Staels, B. Review: Peroxisome proliferatoractivated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab., 2007, 92(2), 386-395.
128. Hardwick, J.P.; Osei-Hyiaman, D.; Wiland, H.; Abdelmegeed, M.A.; Song, B.J. PPAR/RXR regulation of fatty acid metabolism and fatty acid w-hydroxylase (CYP4) isozymes: Implications for prevention of lipotoxicity in fatty liver disease. PPAR Res., 2009, 2009(952743), doi:10.1155/2009/952734.
129. Nanji, A.A. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin. Liver Dis., 2004, 8(3), 559-574.
130. Lu, Y.; Cederbaum, A.I. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med., 2008, 44(5), 723-738.
131. Purohit, V.; Gao, B.; Song, B.J. Molecular mechanisms of alcoholic fatty liver. Alcohol. Clin. Exp. Res., 2009, 33(2), 191-205.
132. Razani, B.; Combs, T.P.; Wang, X.B.; Frank, P.G.; Park, D.S.; Russell, R.G.; Li, M.; Tang, B.; Jelicks, L.A.; Scherer, P.E.; Lisanti, M.P. Caveolin-1-deficient mice are lean, resistant to dietinduced obesity, and show hypertriglyceridemia with adipocytes abnormalities. J. Biol. Chem., 2002, 277(10), 8635-8647.
133. Doege, H.; Grimm, D.; Falcon, A.; Tsang, B.; Storm, T.A.; Xu, H.; Ortegon, A.M.; Kazantzis, M.; Kay, M.A.; Stahl, A. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J. Biol. Chem., 2008, 283(32), 22186-22192.
134. Hubbard, B.; Doege, H.; Punreddy, S.; Wu, H.; Huang, X.; Kaushik, V.K.; Mozell, R.L.; Byrnes, J.J.; Stricker-Krongrad, A.; Chou, C.J.; Tartaglia, L.A.; Lodish, H.F.; Stahl, A.; Gimeno, R.E. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology, 2006, 130(4), 1259-1269.
135. Chang, B.H.J.; Chan, L. Regulation of triglyceride metabolism. III. Emerging role of lipid droplet protein ADFP in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292(6), G1465-1468.
136. Chang, B.H.-J.; Li, L.; Paul, A.; Taniguchi, S.; Nannegari, V.; Heird, W.C.; Chan, L. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol. Cell Biol., 2006, 26(3), 1063-1076.
137. She, P.; Burgess, S.; Shiota, M.; Flakoll, P.; Donahue, E.P.; Malloy, C.R.; Sherry, A.D.; Magnuson, M.A. Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes, 2003, 52(7), 1649-1654.
138. Kim, D. Characteristics of tissue-specific Cre expressing transgenic mice. BioWave, 2005, 7(11), 1-7.
139. Holden, P.; Tugwood, J. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol. Endocrinol., 1999, 22(1), 1-8.
140. Palmer, C.N.A.; Hsu, M.-H.; Griffin, K.J.; Raucy, J.L.; Johnson, E.F. Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol., 1998, 53(1), 14-22.
141. Lambe, K.G.; Woodyatt, N.J.; Macdonald, N.; Chevalier, S.; Roberts, R.A. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol. Lett., 1999, 110(1-2), 119-127.
142. Ferreira, A.V.M.; Parreira, G.G.; Porto, L.C.J.; Mario, É.G.; Delpuerto, H.L.; Martins, A.S.; Botion, L.M. Fenofibrate prevents orotic acid--Induced hepatic steatosis in rats. Life Sci., 2008, 82(15-16), 876-883.
143. Nagai, Y.; Nishio, Y.; Nakamura, T.; Maegawa, H.; Kikkawa, R.; Kashiwagi, A. Amelioration of high fructose-induced metabolic derangements by activation of PPARa. Am. J. Physiol. Endocrinol. Metab., 2002, 282(5), 1180-1190.
144. Kane, C.D.; Francone, O.L.; Stevens, K.A. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPAR alpha. Gene, 2006, 380(2), 84-94.
145. Feldstein, A.E.; Canbay, A.; Guicciardi, M.E.; Higuchi, H.; Bronk, S.F.; Gores, G.J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol., 2003, 39(6), 978-983.
146. Donato, M.T.; Lahoz, A.; Jiménez, N.; Pérez, G.; Serralta, A.; Mir, J.; Castell, J.V.; Gómez-Lechón, M.J. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug. Metab. Disp., 2006, 34(9), 1556-1562.
147. Malhi, H.; Bronk, S.F.; Wemeburg, N.W.; Gores, G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapotosis. J. Biol. Chem., 2006, 281(17), 12093-12101.
148. Rubenstein, K. Overcoming the innovation deficit. Drug and Market Development, 4 May 2000.
149. Leclercq, I.A.; Farrell, G.C.; Field, J.; Bell, D.R.; Gonzalez, F.J.; Robertson, G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest., 2000, 105(8), 1067-1075.
150. Obukowicz, M.G.; Welsch, D.J.; Salsgiver, W.J.; Martin-Berger, C.L.; Chinn, K.S.; Duffin, K.L.; Raz, A.; Needleman, P. Novel, selective d6 or d5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J. Pharmacol. Exp. Ther., 1998, 287(1), 157-166.
151. Feldstein, A.E.; Wieckowska, A.; Lopez, A.R.; Liu, Y.C.; Zein, N.N.; McCullough, A.J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology, 2009, 50(4), 1072-1078.
152. Swagell, C.D.; Henly, D.C.; Morris, C.P. Regulation of human hepatocyte gene expression by fatty acids. Biochem. Biophys. Res. Commun., 2007, 362(2), 374-380.
153. Greco, D.; Kotronen, A.; Westerbacka, J.; Puig, O.; Arkkila, P.; Kiviluoto, T.; Laitinen, S.; Kolak, M.; Fisher, R.M.; Hamsten, A.; Auvinen, P.; Yki-Jarvinen, H. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294(5), G1281-1287.
154. Jin, X.; Ye, Y.F.; Chen, S.H.; Yu, C.H.; Liu, J.; Li, Y.M. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig. Liver Dis., 2009, 41(4), 289-297.
155. Bell, F.S.; Londos, M.; Sztalryd, C. ADRP and Tip47 down regulation results in abnormal lipid droplet morphology lipid metabolism and insulin-stimulated Akt phosphorylation in cultured liver cells. Diabetes, 2006, 55(55), A326.
156. Matin, A.; Gavande, N.; Kim, M.S.; Yang, N.X.; Salam, N.K.; Hanrahan, J.R.; Roubin, R.H.; Hibbs, D.E. 7-Hydroxy-benzopyran-4-one derivatives: A novel pharmacophore of Peroxisome Proliferator-Activated Receptor α and-γ (PPARα and γ) dual agonists. J. Med. Chem., 2009, 52(21), 6835-6850.
157. Myers, R.P. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann. Hepatol., 2009, 8(1), S25-33.
158. Ariz, U.; Mato, J.M.; Lu, S.C.; Martinez Chantar, M.L. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods Mol. Biol., 2010, 593, 109-136.
159. Tarnok, A. Slide-based cytometry for cytomics-a minireview. Cytometry A, 2006, 69(7), 555-562.
160. Brasaemle, D.L.; Wolins, N.E. Isolation of lipid droplets from cells by density gradient centrifugation. Curr. Protoc. Cell Biol., 2005, Chapter 3, unit 3.15, doi 10.1002/0471143030.cb0315s29.
161. Fujimoto, T.; Kogo, H.; Ishiguro, K.; Tauchi, K.; Nomura, R. Caveolin-2 is targeted to lipid droplets, a new "membrane domain" in the cell. J. Cell Biol., 2001, 152(5), 1079-1085.
162. Fujimoto, Y.; Onoduka, J.; Homma, K.J.; Yamaguchi, S.; Mori, M.; Higashi, Y.; Makita, M.; Kinoshita, T.; Noda, J.; Itabe, H.; Takanoa, T. Long-chain fatty acids induce lipid droplet formation in a cultured human hepatocyte in a manner dependent of Acyl-CoA Synthetase. Biol. Pharm. Bull., 2006, 29(11), 2174-2180.
163. Fujimoto, Y.; Itabe, H.; Kinoshita, T.; Homma, K.J.; Onoduka, J.; Mori, M.; Yamaguchi, S.; Makita, M.; Higashi, Y.; Yamashita, A.; Takano, T. Involvement of ACSL in local synthesis of neutral lipids in cytoplasmic lipid droplets in human hepatocyte Huh7. J. Lipid Res., 2007, 48(6), 1280-1292.
164. Miyanari, Y.; Atsuzawa, A.; Usuda, N.; Watashi, K.; Hishiki, T.; Zayas, M.; Bartenschlager, R.; Wakita, T.; Hijikata, M.; Shimotohno, K. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol., 2007, 9(9), 1089-1097.
165. Depla, M.; Uzbekov, R.; Hourioux, C.; Blanchard, E.; Le Gouge, A.; Gillet, L.; Roingeard, P. Ultrastructural and quantitative analysis of the lipid droplet clustering induced by hepatitis C virus core protein. Cell. Mol. Life Sci., 2010, 67(18), 3151-3161.
166. Tauchi-Sato, K.; Ozeki, S.; Houjou, T.; Taguchi, R.; Fujimoto, T. The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition. J. Biol. Chem., 2002, 46(15), 44507-44512.
167. Ohsaki, Y.; Maeda, T.; Fujimoto, T. Fixation and permeabilization protocol is critical for the immunolabeling of lipid droplet proteins. Histochem. Cell Biol., 2005, 124(5), 445-452.
168. Olofsson, S.O.; Boström, P.; Andersson, L.; Rutberg, M.; Levin, M.; Perman, J.; Borén, J. Triglyceride containing lipid droplets and lipid droplet-associated proteins. Curr. Opin. Lipidol., 2008, 19(5), 441-447.
169. Ducharme, N.A.; Bickel, P.E. Minireview: Lipid droplets in lipogenesis and lipolysis. Endocrinology, 2008, 149(3), 942-949.
170. Collinet, C.; Stöter, M.; Bradshaw, C.R.; Samusik, N.; Rink, J.C.; Kenski, D.; Habermann, B.; Buchholz, F.; Henschel, R.; Mueller, M.S.; Nagel, W.E.; Fava, E.; Kalaidzidis, Y.; Zerial, M. Systems survey of endocytosis by multiparametric image analysis. Nature, 2010, 464(7286), 243-249.
171. Koopman, W.J.; Visch, H.J.; Smeitink, J.A.; Willems, P.H. Simultaneous quantitative measurement and automated analysis of mitochondrial morphology, mass, potential, and motility in living human skin fibroblasts. Cytometry A, 2006, 69(1), 1-12.
172. Dejgaard, S.Y.; Murshid, A.; Dee, K.M.; Presley, J.F. Confocal microscopy-based linescan methodologies for intra-Golgi localization of proteins. J. Histochem. Cytochem., 2007, 55(7), 709-719.
173. McDonough, P.M.; Agustin, R.M.; Ingermanson, R.S.; Loy, P.A.; Buehrer, B.M.; Nicoll, J.B.; Prigozhina, N.L.; Mikic, I.; Price, J.H. Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/throughput microscopy and automated image analysis. Assay Drug Dev. Technol., 2009, 7(5), 440-460.
174. Whittaker, R.; Loy, P.A.; Sisman, E.; Suyama, E.; Aza-Blanc, P.; Ingermanson, R.S.; Price, J.H.; McDonough, P.M. Identification of microRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening. J. Biomol. Screen., 2010, 15(7), 798-805.
175. Koopman, R.; Schaart, G.; Hesselink, M.K. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem. Cell. Biol., 2001, 116(1), 63-68.
176. Wüstner, D.; Faergeman, N.J. Chromatic aberration correction and deconvolution for UV sentisive imageing of fluorescent sterols in cytoplasmic lipid droplets. Cytometry A, 2008, 73(8), 727-744.
177. Ma, X.; Cogswell, A.; Li, Z.; Lee, K. Particle size analysis of dispersed oil and oil-mineral aggregates with an automated ultraviolet epi-fluorescence microscopy system. Environ. Technol., 2008, 29(7), 739-748.
178. Hwang, J.T.; Kim, S.H.; Lee, M.S.; Kim, S.H.; Yang, H.J.; Kim, M.J.; Kim, H.S.; Ha, J.; Kim, M.S.; Kwon, D.Y. Anti-obesity effects of ginsenoside Rh2 are associated with the activation AMPK signaling pathway in 3T3-L1 adipocyte. Biochem. Biophysiol. Res. Commun., 2007, 364(4), 1002-1008.
179. Adams, L.A.; Angulo, P.; Lindor, K.D. Nonalcoholic fatty liver disease. CMAJ, 2005, 172(7), 899-905.
180. Postic, C.; Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest., 2008, 118(3), 829-838.
181. Dans, A.M.; Villarruz, M.V.; Jimeno, C.A.; Javelosa, M.A.; Chua, J.; Bautista, R.; Velez, G.G. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J. Clin. Epidemiol., 2007, 60(6), 554-559.